As the American population ages, incidences of osteoarthritis are more commonly occurring. In fact, osteoarthritis affects more than 70% of adults between 55 and 78 in America. With osteoarthritis on the rise, it is even more imperative to come up with effective treatments that allow patients to resume their normal life routine.
Viscosupplements treat osteoarthritis by using hyaluronic acid (HA) to reduce inflammation and cartilage degeneration. AQ Therapeutics’ Joint Relief Solution (JXN) is a viscosupplement that specifically uses high molecular weight HA and also combines patented growth factor technology to create a formulation that is effective in treating osteoarthritis.
High Molecular Weight HA vs. Cross-Linked HA
In cross-linked HA (Figure A), when the compound breaks down, small fragments are created, leading to further inflammation and degeneration. To prevent this issue, AQ Therapeutics uses high molecular weight HA (Figure B), which when broken down, create longer chains of HA (vs. shorter) and do not induce an inflammatory response. Additionally, these layers create a space for growth factors which contain anti- inflammatory cytokines that may possibly regenerate cartilage.
Human Fibroblast Conditioned Media (Growth Factors),
CD44 Antagonist, BPC-157, Thymosin Beta-4, GHK-CU, IGF-1EC
Directions For Use
The AQ JXN (Joint Relief Solution) is meant for injection into intra-articular areas only.